Norris Medicines
add_icon

Norris Medicines

14.00
+0.29
(2.12%)
Market Cap
13.99 Cr
PE Ratio
-24.48
Volume
555.00
Day High - Low
15.00 - 13.77
52W High-Low
22.10 - 12.50
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
13.99 Cr
EPS
-1.24
PE Ratio
-24.48
PB Ratio
-0.87
Book Value
-15.82
EBITDA
-0.20
Dividend Yield
0.00 %
Return on Equity
8.32
Debt to Equity
0.00
Forecast For
Actual

Company News

View All News
Caret
neutral
Norris Medicines Limited's Board approved unaudited financial results for the quarter and year ended December 31, 2025, following their February 14, 2026 board meeting.
neutral
Norris Medicines Limited announces resignation of Independent Director Ms. Sathya Venkatachalam effective December 12, 2025, citing personal reasons.
positive
Norris Medicines Limited successfully completed regulatory audit by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) on December 9, 2025, with no critical observations reported.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
234.55
#1 18,336.52
#1 10.03
#1 99,561.70
11.11
#1 1,821
2.58
41.44
51.89
8,294.60
25.97
551.40
#1 55,040.00
70
678.95
34.50
53.29
7,993.50
31.64
262.80
28.63
87
#1 1,151.35
29.21
413.20
2,908.93
13.93
387.50
-25.38
407
-79.51
31.44
134.92
2,409.06
29.89
262.20
79.10
23
563.64
36.11
218.90
2,140.29
44.42
367.20
5,071.83
20
-167.33
28.40
395.25
1,878.55
38.19
89.60
14.72
42
34.62
-
122.88
1,774.86
27.29
312.50
136.92
40
52.80
28.73
628.25
943.42
14.83
1,801.50
3.48
53
36.84
39.16
475.50
859.27
66.47
21.10
559.38
2
2.30
91.02
Growth Rate
Revenue Growth
3.51 %
Net Income Growth
-
Cash Flow Change
200.00 %
ROE
-4.48 %
ROCE
37.56 %
EBITDA Margin (Avg.)
24.28 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
Revenue
19
19
21
14
16
8
12
10
8
6
6
10
Expenses
17
18
21
16
17
10
14
10
7
6
6
9
EBITDA
2
1
0
-2
-1
-2
-2
0
1
-0
-0
0
Operating Profit %
9 %
4 %
-0 %
-14 %
-4 %
-27 %
-14 %
-1 %
11 %
-3 %
-5 %
0 %
Depreciation
1
1
1
1
1
1
1
1
1
1
1
0
Interest
1
1
1
1
1
1
2
2
2
0
0
1
Profit Before Tax
0
-0
-1
-3
-2
-4
-4
-2
-1
-1
-1
-1
Tax
1
-0
-0
-1
-0
-1
1
1
1
0
0
0
Net Profit
-1
0
-1
-3
-2
-3
-5
-3
-2
-1
-1
-1
EPS in ₹
-1.04
0.04
-0.77
-2.51
-1.68
-2.84
-4.96
-3.26
-1.75
-1.19
-1.24
-0.60

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
18
18
22
21
20
21
20
14
14
14
14
Fixed Assets
9
8
10
9
9
8
8
7
7
6
5
Current Assets
7
7
9
8
7
7
8
4
5
6
6
Capital Work in Progress
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
Other Assets
10
10
12
11
12
12
12
7
7
8
9
Total Equity & Liabilities
18
18
22
21
20
21
20
14
14
14
14
Current Liabilities
5
5
10
11
9
8
12
7
8
9
10
Non Current Liabilities
8
8
8
8
11
15
16
18
18
19
19
Total Equity
5
5
5
2
0
-3
-7
-11
-12
-14
-15
Reserve & Surplus
-5
-5
-5
-8
-10
-12
-17
-21
-22
-24
-25
Share Capital
10
10
10
10
10
10
10
10
10
10
10

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-2
-0
0
0
0
0
0
0
0
0
0
Investing Activities
-1
-0
-2
-0
-0
0
-0
-0
0
0
0
Operating Activities
-1
1
-1
1
-2
-3
1
-1
1
0
1
Financing Activities
0
-1
3
-1
2
3
-1
1
-1
-0
-1

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
34.04 %
34.04 %
34.04 %
34.04 %
34.04 %
34.04 %
34.04 %
34.04 %
34.04 %
34.01 %
34.01 %
34.01 %
34.01 %
34.01 %
34.01 %
34.00 %
34.00 %
34.00 %
34.00 %
34.00 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
0.07 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
20.60 %
20.57 %
20.56 %
20.52 %
20.60 %
20.59 %
20.60 %
20.59 %
20.56 %
20.63 %
20.66 %
20.67 %
20.70 %
20.71 %
20.72 %
20.73 %
20.76 %
20.78 %
20.79 %
20.79 %
Others
45.29 %
45.31 %
45.32 %
45.36 %
45.29 %
45.30 %
45.28 %
45.30 %
45.33 %
45.29 %
45.25 %
45.25 %
45.22 %
45.21 %
45.20 %
45.21 %
45.17 %
45.15 %
45.14 %
45.14 %
No of Share Holders
0
25,010
25,032
25,019
25,141
25,290
25,294
25,329
25,326
25,256
25,242
25,317
25,517
25,400
25,498
25,659
25,815
25,950
25,895
25,791

Announcements

Outcome Of The Board Meeting Held On 14Th February 2026 Pursuant To Regulation 30 And 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.Feb 14, 2026
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14Th February 2026 Pursuant To Regulation 30 And 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.Feb 14, 2026
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Closure Of Case ID 223728 For Reclassification Of Promoter.Feb 13, 2026
Board Meeting Intimation for Intimation Under Regulation 29 Of SEBI Listing Obligation And Disclosure Requirements 2015 For Holding Board Meeting For Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended December 31St 2025 And OthFeb 11, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 04, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 12, 2026
Closure of Trading WindowDec 26, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorDec 12, 2025
Intimation Regarding Completion Of NAFDAC Audit (Nigeria) Of Norris Medicines Limited.Dec 12, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderDec 11, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Friday November 14 2025Nov 14, 2025
Board Meeting Intimation for Intimation Under Regulation 29 Of SEBI Listing Obligation And Disclosure Requirements 2015 For Holding Board Meeting For Approval Of Un-Audited Financial Results For The Quarter Ended September 30Th 2025 And Other Matters.Nov 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Voting Results For 34Th AGM.Sep 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 29, 2025
Proceedings Of The 34Th Annual General Meeting Of Norris Medicines Limited Held For The Financial Year 2024-2025 On September 29Th 2025.Sep 29, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 29, 2025
Closure of Trading WindowSep 25, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 12, 2025
Intimation Of Cutoff Date For Remote E-Voting And Closure Of Register Of Members & Share Transfer Books At 34Th Annual General Meeting.Sep 05, 2025
Letter To Shareholders In Terms Of Regulation 36(1)(B) Of The SEBI Listing Regulations.Sep 05, 2025
Reg. 34 (1) Annual Report.Sep 05, 2025
Notice Of 34Th Annual General Meeting Of The Company.Sep 05, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 01, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On Monday 01St September 2025 Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.Sep 01, 2025
Outcome Of Board Meeting Held On Thursday 14Th August 2025 Pursuant To Regulation 30 And Regulation 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.Aug 14, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday 14Th August 2025 Pursuant To Regulation 30 And Regulation 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.Aug 14, 2025
Board Meeting Intimation for Intimation Under Regulation 29 Of SEBI Listing Obligation And Disclosure Requirements 2015 For Holding Board Meeting For Approval Of Un-Audited Financial Results For The Quarter Ended June 30Th 2025 And Other Matters.Aug 11, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 18, 2025
Closure of Trading WindowJun 27, 2025
Outcome Of The Board Meeting Held On May 28 2025_Pursuant To Regulation 30 And Regulation 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.May 28, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On May 28 2025_Pursuant To Regulation 30 And Regulation 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.May 28, 2025
Board Meeting Intimation for Intimation Under Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements 2015) For Holding Board Meeting For Approval Of Audited Financial Results For The Quarter And Year Ended 31St March 2025 And Other Matters.May 23, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 29, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 04, 2025
Closure of Trading WindowMar 29, 2025
Integrated Filing (Financial)Feb 14, 2025
Outcome Of Board Meeting Held On 13Th February 2025 Pursuant To Regulation 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.Feb 13, 2025
Board Meeting Outcome for Outcome Of Board Meeting Dated (Board Meeting Date) Pursuant To Regulation 30 And 31A (8) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.Feb 13, 2025
Board Meeting Intimation for Notice Of The Board Meeting Of 2024-25 Pursuant To Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.Feb 10, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 14, 2025
Closure of Trading WindowDec 31, 2024
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 For Receipt Of Request Letter From Promoter Of The Company For Reclassification From Promoter & Promoter Group To Public Category.Dec 23, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementDec 06, 2024
Declaration Of Non-Applicability Of Regulation 23(9) Of SEBI (LODR) Regulations, 2015 For Half Year Ended 30.09.2024.Nov 14, 2024
Adoption Of Financials In Board Meeting Held On Thursday, 14Th November, 2024 Pursuant To Regulation 30 And 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.Nov 14, 2024
Board Meeting Outcome for Outcome Of The Board Meeting Held On Thursday, 14Th November, 2024 Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.Nov 14, 2024
Board Meeting Intimation for Notice Of The Board Meeting Of 2024-25 Pursuant To Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.Nov 11, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 14, 2024
Result Of Voting And Scrutinizers Report - 33Rd AGM Held On 30Th September 2024.Oct 01, 2024

Technical Indicators

RSI(14)
Neutral
49.87
ATR(14)
Less Volatile
1.25
STOCH(9,6)
Neutral
53.26
STOCH RSI(14)
Neutral
49.43
MACD(12,26)
Bullish
0.05
ADX(14)
Weak Trend
10.71
UO(9)
Bearish
50.15
ROC(12)
Uptrend And Accelerating
5.97
WillR(14)
Neutral
-44.77